Marco Fabbri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Marco Fabbri has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Chiara Reali
Unit of Hygiene and Public Health Forlì-Cesena, Department of Public Health, Romagna Local Health Authority, 47522 Cesena, Italy
1 shared publication - Elizabeth Bakken
Unit of Hygiene and Public Health Rimini, Department of Public Health, Romagna Local Health Authority, 47624 Rimini, Italy
1 shared publication - Gian Luigi Belloli
Unit of Hygiene and Public Health Forlì-Cesena, Department of Public Health, Romagna Local Health Authority, 47522 Cesena, Italy
1 shared publication - Gianpiero Mancini
Department of Public Health, Romagna Local Health Authority, 48121 Ravenna, Italy
1 shared publication - Giorgio Cavalli
School of Hygiene and Preventive Medicine, University of Ferrara, 44121 Ferrara, Italy
1 shared publication - Giulia Silvestrini
Unit of Hygiene and Public Health Ravenna, Department of Public Health, Romagna Local Health Authority, 48121 Ravenna, Italy
1 shared publication
Latest Publications
- Open Access
From Knowledge to Action: Enhancing Herpes Zoster Vaccine Uptake in Diabetic Patients Through Targeted Interventions
Background/Objectives: Vaccinations are a cost-effective strategy to reduce morbidity and mortality from infectious diseases, particularly in individuals with diabetes mellitus (DM). Despite recommendations for routine vaccination, uptake among adults with DM remains suboptimal. This study evaluates the effectiveness of interventions aimed at increasing Herpes Zoster (HZ) vaccine coverage in diabetic patients. Methods: This study included diabetic patients residing in the Romagna Local Health Authority (1.2 million inhabitants). Two complementary strategies were implemented: patient-oriented interventions (reminders/recalls) and provider-focused actions to engage general practitioners and diabetologists. Vaccination coverage in December 2023 was compared with December 2024, stratified by age, sex, and nationality. Primary outcomes were changes in coverage and intervention impact. Multivariate logistic regression assessed sociodemographic determinants of adherence. Results: As of 31 December 2023, 5182 diabetic patients had received at least one dose of Herpes Zoster vaccine (7.4% coverage). In 2024, overall coverage (11.1%) increased across all sociodemographic groups. Coverage rose to 12.8% in males and 9.0% in females and to 11.7% among Italian citizens, while foreign citizens showed lower absolute levels but a greater proportional increase. By age, individuals born after 1958 exhibited the largest relative growth, whereas those born in 1952–1958 reached the highest absolute coverage in 2024. Male sex, the 1952–1958 birth cohort, and Italian citizenship were associated with a higher likelihood of vaccination in both years. Conclusions: Our findings show a positive trend in Herpes Zoster vaccination among diabetic patients in Romagna HLA, driven by patient reminders, provider engagement, and age-targeted campaigns, while persistent sociodemographic disparities underscore the need for tailored strategies to optimize coverage.
Open AccessFrom Knowledge to Action: Enhancing Herpes Zoster Vaccine Uptake in Diabetic Patients Through Targeted Interventions
Background/Objectives: Vaccinations are a cost-effective strategy to reduce morbidity and mortality from infectious diseases, particularly in individuals with diabetes mellitus (DM). Despite recommendations for routine vaccination, uptake among adults with DM remains suboptimal. This study evaluates the effectiveness of interventions aimed at increasing Herpes Zoster (HZ) vaccine coverage in diabetic patients. Methods: This study included diabetic patients residing in the Romagna Local Health Authority (1.2 million inhabitants). Two complementary strategies were implemented: patient-oriented interventions (reminders/recalls) and provider-focused actions to engage general practitioners and diabetologists. Vaccination coverage in December 2023 was compared with December 2024, stratified by age, sex, and nationality. Primary outcomes were changes in coverage and intervention impact. Multivariate logistic regression assessed sociodemographic determinants of adherence. Results: As of 31 December 2023, 5182 diabetic patients had received at least one dose of Herpes Zoster vaccine (7.4% coverage). In 2024, overall coverage (11.1%) increased across all sociodemographic groups. Coverage rose to 12.8% in males and 9.0% in females and to 11.7% among Italian citizens, while foreign citizens showed lower absolute levels but a greater proportional increase. By age, individuals born after 1958 exhibited the largest relative growth, whereas those born in 1952–1958 reached the highest absolute coverage in 2024. Male sex, the 1952–1958 birth cohort, and Italian citizenship were associated with a higher likelihood of vaccination in both years. Conclusions: Our findings show a positive trend in Herpes Zoster vaccination among diabetic patients in Romagna HLA, driven by patient reminders, provider engagement, and age-targeted campaigns, while persistent sociodemographic disparities underscore the need for tailored strategies to optimize coverage.